Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30946635 | 0.88 | KDM4E (0.55) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL21199308 | 0.88 | KDM4E (0.55) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL25873500 | 0.83 | CYP2D6 (0.58) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL25873499 | 0.82 | CYP1A2 (0.56) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6532154 | 0.79 | KDM4E (0.57) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL5499989 | 0.79 | KDM4E (0.57) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29567519 | 0.77 | CYP2D6 (0.65) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL28748593 | 0.77 | CYP2D6 (0.65) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL30803039 | 0.76 | CYP2C19 (0.57) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL19436432 | 0.76 | CYP2C19 (0.57) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374024-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11708367-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708367-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, ERBB3, MAP3K6 | KDM4E 2929/4885ALDH1A1 3215/4885SMN1; SMN2 1215/4885 |
| US-20230374024-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, ERBB3, MAP3K6 | KDM4E 2929/4885ALDH1A1 3215/4885SMN1; SMN2 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.